Decreased Liver Fibrosis in Patients with Hepatitis C Virus (HCV)/Human Immunodeficiency Virus (HIV) Coinfection After Treatment with Sofosbuvir/Daclatasvir

Andreas Jonathan, Rudi Wisaksana, Nenny Agustanti

Abstract


Background: Hepatitis C Virus (HCV)/Human Immunodeficiency Virus (HIV) co-infection increases the progression of liver fibrosis to advanced liver disease and death. The aim of this study is to determine whether the changes of liver fibrosis occur in HCV/HIV coinfection patients after therapy with Sofosbuvir/daclatasvir.

Method: This study used a quasi-experimental study design without a control group. The study subjects were HCV / HIV coinfection patients who received Sofosbuvir / daclatasvir therapy in the Gastroentero-Hepatology Clinic of Dr. Hasan Sadikin Hospital. In this study measurement of liver fibrosis was carried out by using AST to Platelet Ratio Index (APRI) and Fibrosis-4 Index (FIB-4) before therapy and when SVR-24 was achieved.

Results: The study involved 29 subjects. Most of the research subjects were men, with an average age of 40.38 years (SD 3.48). From the results of this study, we found a decrease in APRI scores and FIB-4 index when HCV / HIV coinfection patients, that were treated with Sofosbuvir / Daclatasvir, achieved SVR 24. The median of APRI scores before therapy and after SVR-24 was decreased from 0.41 to 0.28 (95% CI: 0.01 - 0.23, p-value 0,01) and the median of FIB-4 Index before therapy and after the SVR 24 was decreased from 0.94 to 0.81 (95% CI: -0, 04 - 0.35, p-value 0.28).

Conclusion: This study concluded that therapy using Sofosbuvir / Daclatasvir in HCV / HIV coinfected patients has very good effectiveness and can reduce liver fibrosis.


Keywords


HCV/HIV coinfection; liver fibrosis; Sofosbuvir/Daclatasvir

Full Text:

PDF


DOI: https://doi.org/10.24871/202201987-95

Refbacks

  • There are currently no refbacks.


Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License